Nystagmus treatment depends heavily on the type of nystagmus a person has, its underlying cause, and which symptoms matter most. There is no single cure, but a growing toolkit of medications, surgeries, optical devices, and rehabilitation techniques can reduce the involuntary eye movements, improve visual acuity, relieve oscillopsia (the sensation that the world is bouncing), or shift the eyes’ resting point so the head doesn’t have to turn to compensate. The right combination varies from person to person, and what works well for downbeat nystagmus may do nothing for the infantile form.
Why the Type of Nystagmus Dictates the Treatment
Most childhood nystagmus falls into a few benign categories: idiopathic infantile nystagmus, nystagmus linked to an eye condition, or latent nystagmus. These forms typically appear around three months of age and do not cause oscillopsia, the visual bouncing that makes acquired nystagmus so disorienting. Fewer than one in five childhood cases are acquired forms that signal a neurological problem and need imaging and further workup.1PubMed. Infantile and acquired nystagmus in childhood In adults, acquired nystagmus more often stems from conditions like multiple sclerosis, cerebellar degeneration, or brainstem stroke. That distinction matters because the medications that quiet cerebellar-driven downbeat nystagmus act on entirely different pathways from those that help the pendular nystagmus seen in multiple sclerosis.
The impact on daily life also goes beyond what a standard eye chart captures. Visual acuity with nystagmus can fluctuate minute to minute or day to day, and the effects on reading speed, depth perception, and confidence in social situations are rarely measured in routine exams.2PubMed Central. Management of nystagmus in children: a review of the literature and current practice in UK specialist services Knowing which form you or your child has is the first step toward choosing the right treatment strategy.
Medications for Downbeat Nystagmus
Downbeat nystagmus, where the eyes drift slowly downward and then snap back up, is one of the best-studied forms when it comes to drug treatment. The aminopyridine family, particularly 4-aminopyridine (4-AP, also called dalfampridine or fampridine), has the strongest evidence. In a study of 15 patients, 4-AP reduced the downward drift during straight-ahead gaze in 12, with the most dramatic improvement in patients whose nystagmus stemmed from cerebellar atrophy. Their average slow-phase drift dropped from roughly 5 degrees per second to less than 1 degree per second. The drug appeared to work by restoring the brain’s gaze-holding circuits, likely through increasing the excitability of Purkinje cells in the cerebellar flocculus.3PubMed. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus
A related compound, 3,4-diaminopyridine (3,4-DAP), also reduces downbeat nystagmus and was confirmed in a placebo-controlled trial of 17 patients.4Progress in Brain Research. Aminopyridines for the treatment of cerebellar and ocular motor disorders When the two drugs were compared head to head at 10-mg doses, 4-AP came out ahead. Ninety minutes after dosing, mean slow-phase velocity with 4-AP had dropped to about 1.2 degrees per second, compared with about 3 degrees per second on 3,4-DAP.5PubMed. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus In practice, 4-AP tends to be the first-line medication tried for downbeat nystagmus, though access varies by country and the drug is not universally approved for this indication.
Medications for Acquired Pendular Nystagmus
Acquired pendular nystagmus, which produces a shimmering, oscillating eye movement rather than the jerk pattern of downbeat nystagmus, most commonly appears in people with multiple sclerosis. Two drugs dominate the evidence: gabapentin (an anticonvulsant) and memantine (better known for its use in Alzheimer’s disease). Both reduce the oscillation and can improve visual acuity, but they work differently in different patients.
A retrospective study found that gabapentin improved nystagmus in 10 of 13 patients whose pendular nystagmus was caused by MS. In the three MS patients who did not respond to gabapentin, memantine improved visual acuity instead.6PubMed Central. The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study A crossover trial comparing the two drugs directly found that memantine at 40 to 60 mg completely stopped the pendular nystagmus in eight eyes across four patients, while gabapentin at up to 1,200 mg achieved complete cessation in only two additional eyes. Near visual acuity improved by a clinically meaningful amount in about two-thirds of eyes treated with memantine versus half with gabapentin.7PubMed. Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin
So which one should be tried first? A separate study looking at functional visual outcomes concluded that while both drugs reduce pendular nystagmus, gabapentin had better tolerability, and the authors recommended it as the first-line agent.8PubMed. Gabapentin and Memantine for Treatment of Acquired Pendular Nystagmus: Effects on Visual Outcomes In practice, many clinicians start with gabapentin and switch to memantine if the response is inadequate or side effects are a problem. The two drugs can also complement each other, since patients who fail one sometimes respond to the other.
Baclofen for Periodic Alternating Nystagmus
Periodic alternating nystagmus is a rarer pattern in which the direction of the jerk reverses every couple of minutes. It can be acquired (usually from cerebellar disease) or congenital. Baclofen, a GABA-receptor agonist commonly used as a muscle relaxant, has been the standard medical treatment for decades. In acquired periodic alternating nystagmus, baclofen at 30 mg per day abolished the nystagmus and relieved oscillopsia in two patients studied early on.9PubMed. Treatment of periodic alternating nystagmus
Whether baclofen also helps congenital periodic alternating nystagmus has been debated. A series of eight children with the congenital form found that four had improved head posture and four gained a line of visual acuity after treatment. Five of six surveyed patients or families were pleased with the trial. However, drowsiness was the most common side effect, and treatment was withdrawn in four of the eight patients due to side effects or lack of benefit.10Strabismus. Baclofen for Patients with Congenital Periodic Alternating Nystagmus At least one individual case report also found that baclofen reduced congenital periodic alternating nystagmus and improved the patient’s oscillopsia, challenging the earlier view that it only works in acquired cases.11PubMed. A case of periodic alternating nystagmus: with a special reference to the efficacy of baclofen treatment The takeaway is that a trial of baclofen is reasonable even in congenital periodic alternating nystagmus, but expectations should be measured and side effects monitored.
Topical Eye Drops for Infantile Nystagmus
For infantile nystagmus syndrome, systemic medications have limited evidence. An unexpected alternative has emerged: brinzolamide, a carbonic anhydrase inhibitor normally prescribed as a glaucoma eye drop. In a study testing topical brinzolamide in infantile nystagmus, the drug improved foveation (the ability of the eye to hold a target on the sharpest part of the retina) by roughly 52%, and it broadened the range of gaze angles over which foveation quality was good from 20 degrees to 30 degrees.12PubMed. Effects of topical brinzolamide on infantile nystagmus syndrome waveforms: eyedrops for nystagmus A subsequent placebo-controlled trial confirmed that brinzolamide significantly improved nystagmus waveform characteristics and binocular letter visual acuity compared with both placebo and baseline.13PubMed. Topical brinzolamide (Azopt) versus placebo in the treatment of infantile nystagmus syndrome (INS)
The appeal of an eye drop is obvious: it avoids the sedation and systemic side effects that come with oral medications. Brinzolamide is not yet a standard prescription for nystagmus in most clinics, but it represents one of the few pharmacological options specifically tested in the infantile form.
Surgery to Shift or Calm the Eyes
When someone with infantile nystagmus has a “null zone,” a specific gaze direction where the nystagmus quiets and vision is best, they often adopt an abnormal head posture, turning or tilting the head to keep their eyes in that sweet spot. Surgery can reposition the eye muscles so the null zone sits in the primary (straight-ahead) position, eliminating the need for the awkward head turn.
The Anderson-Kestenbaum procedure is the classic operation for this. It involves weakening and tightening specific horizontal eye muscles on both eyes to shift the null zone forward. A long-term outcomes study found that about 44% of patients achieved what the researchers defined as an optimal result (abnormal head position reduced to 10 degrees or less), and 88% had at least some improvement in their head posture by their last follow-up visit.14PubMed Central. The long-term outcomes of the Anderson-Kestenbaum procedure A separate evaluation of displacement surgeries including the Kestenbaum procedure confirmed that they effectively correct abnormal head posture, improve visual acuity in the primary position, and damp the nystagmus itself in congenital nystagmus patients with off-center null points.15PubMed Central. Evaluation of the Role of Displacement Surgery in the Management of Congenital Nystagmus
A different surgical concept, tenotomy and reattachment, detaches and then re-secures the eye muscles without changing their position. The idea is that disrupting the proprioceptive feedback from the muscles alters the nystagmus waveform. A study testing whether adding an extra suture (augmented tenotomy) would enhance the effect found that the additional suture did not improve foveation quality and in some cases diminished the benefit of the standard procedure.16PubMed Central. Effects of augmented tenotomy and reattachment in the infantile nystagmus syndrome Standard tenotomy and reattachment can still broaden the range of gaze angles with good foveation, but the technique remains somewhat experimental and is typically considered when the null zone is already centered and the goal is to improve waveform quality rather than shift head posture.
Optical Approaches and Prisms
Contact lenses do more for nystagmus than just correct refractive error. Research has shown that the therapeutic effect comes partly from the lenses’ physical contact with the cornea, which sends sensory signals through the trigeminal nerve and interferes with the neurological circuits driving the nystagmus. This was demonstrated by applying topical anesthetics to block the sensory input from the lenses, which reduced their dampening effect. The resulting broadening of the zone of high-quality foveation goes beyond what simple optical correction or reduced aberrations would explain.17PubMed Central. Infantile nystagmus syndrome: Broadening the high-foveation-quality field with contact lenses
Prism glasses offer another non-invasive option, particularly for children with an abnormal head posture. A retrospective study of pediatric nystagmus patients fitted with yoked prisms found that the average abnormal head position dropped from about 17 degrees to under 5 degrees for distance viewing, and from about 13 degrees to under 4 degrees at near. On average, each prism diopter corrected roughly 3.5 degrees of head turn. Visual acuity also showed a modest improvement.18PubMed Central. Correction of Abnormal Head Position in Pediatric Nystagmus Using Yoked Low-Value Prism Glasses: A Retrospective Study Prisms do not eliminate the nystagmus itself, but they effectively redirect the line of sight so the null zone aligns with a more natural head position.
Biofeedback Training
Biofeedback aims to teach the brain to hold fixation more steadily by giving the patient real-time audio or visual cues tied to their eye movements. A pilot study of children with idiopathic infantile nystagmus found that audio-visual biofeedback training improved distance visual acuity, reading speed (from about 75 to 105 words per minute on average), stereopsis, and contrast sensitivity. Fixation stability improved substantially, and quality-of-life scores rose as well.19PubMed Central. Post audio-visual biofeedback training visual functions and quality of life in paediatric idiopathic infantile nystagmus: A pilot study
A case report of a child with idiopathic nystagmus who underwent audio-luminous biofeedback training found that visual acuity improved from 20/60 to 20/30 in one eye and from 20/80 to 20/32 in the other within three months. Nystagmus amplitude dropped from about 13 degrees to 2.5 degrees. At 12 months, some of the gains had partially regressed, with acuity settling at 20/40, suggesting that periodic maintenance sessions may be needed.20Arquivos Brasileiros de Oftalmologia. Visual outcomes of audio-luminous biofeedback training for a child with idiopathic nystagmus Biofeedback is non-invasive and carries essentially no physical risk, though access to the specialized equipment and trained therapists remains limited.
Botulinum Toxin Injections
Injecting botulinum toxin behind the eye to weaken the muscles and suppress nystagmus has been tried, but enthusiasm has been tempered by practical limitations. In a small series, retrobulbar botulinum toxin abolished or reduced all components of nystagmus in the treated eye for about two to three months per injection.21American Journal of Ophthalmology. Unsatisfactory Treatment of Acquired Nystagmus With Retrobulbar Injection of Botulinum Toxin The researchers themselves described the results as unsatisfactory overall, because the temporary paralysis also caused double vision and drooping eyelids, and the effect wore off within weeks. For most patients, repeated injections with predictable side effects are not a practical long-term strategy, though the approach is occasionally considered when other options have failed.
Vibration and Somatosensory Stimulation
An unusual finding in nystagmus research is that simply applying vibration to the skin of the forehead or neck can dampen congenital nystagmus in some patients. A study of 13 individuals found positive effects in nine. Vibration on the neck was more effective than vibration on the forehead, and more effective than electrical stimulation. The improvement in visual acuity depended on how much the stimulation lengthened foveation periods rather than merely reducing the amplitude of the eye movement.22Vision Research. The effects of afferent stimulation on congenital nystagmus foveation periods This kind of approach has not made it into standard clinical practice, but it hints at how sensory inputs outside the visual system can modulate nystagmus circuits, a principle that also underlies the contact-lens effect described earlier.
Emerging Approaches
Several treatment strategies are still at the proof-of-concept stage but worth knowing about. Repetitive transcranial magnetic stimulation (rTMS) of the cerebellum was tested in a small cohort of patients with persistent dizziness and nystagmus after a brainstem stroke. The stimulation reduced dizziness scores and the nystagmus itself disappeared during the treatment period.23PubMed. Effects of cerebellar magnetic stimulation on chronic post-lateral medullary infarction dizziness: A proof-of-principle cohort study Whether this translates into a lasting or broadly applicable treatment is unknown, but it opens the door to non-invasive brain stimulation as a future option.
Gene therapy is being explored for infantile nystagmus that is caused by inherited retinal diseases. Conditions like achromatopsia, Leber congenital amaurosis, congenital stationary night blindness, and certain subtypes of retinitis pigmentosa can all present with nystagmus in infancy. A growing number of clinical trials are testing AAV-based gene therapies that target the retinal gene defect directly, and early results suggest that if the underlying retinal disease can be treated, the nystagmus may improve as a downstream consequence.24PubMed Central. Infantile Nystagmus Syndrome-Associated Inherited Retinal Diseases: Perspectives from Gene Therapy Clinical Trials Gene therapy for nystagmus-associated retinal disease is still in trials, but it represents a fundamentally different approach: fixing the cause rather than managing the symptom.
Assistive Technology for Oscillopsia
For people whose nystagmus causes severe oscillopsia, technology that stabilizes the visual image can make a real difference, even if it doesn’t treat the nystagmus itself. One approach uses augmented-reality eyewear with real-time image stabilization software. In testing, the mean number of lines a patient could read on an eye chart dropped dramatically with head movement (from about 8 lines at rest to under 3 with movement), but jumped back to about 6 lines when the stabilization software was active.25PubMed. The use of real-time image stabilization and augmented reality eyewear in the treatment of oscillopsia
A separate pilot study tested real-time computer-based visual feedback for downbeat nystagmus, where the display shifted in sync with the eye’s slow-phase drift to keep the image stable on the retina. The researchers found that the system effectively compensated for the drift and improved visual acuity, offering a potential aid for reading on screens.26PubMed Central. Real-time computer-based visual feedback improves visual acuity in downbeat nystagmus – a pilot study As virtual-reality and augmented-reality headsets continue to shrink and improve, these compensatory strategies may become practical for daily use beyond the laboratory.
Smartphone-Based Monitoring
One practical challenge in nystagmus treatment is knowing whether a medication or intervention is actually working. Slow-phase velocity, the key metric clinicians track, traditionally requires specialized video-oculography equipment. A smartphone application called EyePhone has shown it can quantify nystagmus slow-phase velocity accurately enough to track treatment response over time.27PubMed Central. Quantifying Induced Nystagmus Using a Smartphone Eye Tracking Application (EyePhone) If tools like this become validated and widely available, they could let patients and their doctors monitor changes between office visits, making it much easier to fine-tune drug doses or decide when a treatment switch is warranted.